What question did this study set out to answer?

This research aims to evaluate the tolerability and effectiveness of gilteritinib in post-transplant relapse for R/R FLT3-mutated AML patients.

April 16, 2026Transplantation and Cellular TherapyOpen Access

Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapse/refractory FLT3-mutated acute myeloid leukemia

View Full Paper

Ask AI

Bookmark

Authors

YAYasuyuki Arai MOMarie Ohbiki MKMio Kurata

Discussion

Member takes

Implication

Nation-wide surveillance demonstrates that gilteritinib improves relapse-free survival in R/R FLT3-mutated AML post-transplant, suggesting effective maintenance treatment.

Key Points

This research aims to evaluate the tolerability and effectiveness of gilteritinib in post-transplant relapse for R/R FLT3-mutated AML patients.
Conducted nationwide surveillance using a national registry in Japan.
Analyzed data of R/R FLT3-mutated AML patients treated with gilteritinib before and/or after allogeneic HSCT.
Summarized dose, safety, and outcomes such as relapse-free survival (RFS).
Among 120 patients treated with gilteritinib, 55 received maintenance treatment post-HSCT.
Patients receiving gilteritinib post-HSCT had a 3-year RFS of 58.8% compared to 36.4% without it (p < 0.001).
Serious adverse events led to dose adjustments in about 52.7% of cases.

Cite This Study

Arai et al. (2026) studied this question.

synapsesocial.com/papers/69e07bc12f7e8953b7cbd5de https://doi.org/10.1016/j.jtct.2026.03.042

View Full Paper

Ask AI

Bookmark

Implication

Nation-wide surveillance demonstrates that gilteritinib improves relapse-free survival in R/R FLT3-mutated AML post-transplant, suggesting effective maintenance treatment.

Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapse/refractory FLT3-mutated acute myeloid leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Maintenance treatment with gilteritinib suppresses post-transplant relapse in relapse/refractory FLT3-mutated acute myeloid leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider